Toronto, Ontario--(Newsfile Corp. - September 10, 2020) - Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, MD Anderson Cancer Center in Houston, Texas for 41 years.
He has published over 200 peer-reviewed scientific papers, invited articles and book chapters, and participated in the validation and FDA clearance process for most every commercial serum cancer marker currently in use in the United States. Dr. Fritsche holds 3 patents and 2 patents pending.
Additionally, Dr. Fritsche served as an invited consultant/advisor to the Food and Drug Administration, the National Cancer Institute, on the Laboratory Practice Guidelines Committee for the National Academy of Clinical Biochemistry, on the Editorial Board of six international scientific journals, and as a consultant to many major international diagnostic companies. Previously, he served on the Expert Panel for developing Tumor Marker Practice Guidelines for the American Society of Clinical Oncology (ASCO) from its inception until his retirement from MD Anderson Cancer Center.
Dr. Fritsche has served as President of the Clinical Ligand Assay Society (CLAS) and various national committees for both the Clinical Ligand Assay Society (CLAS) and American Association for Clinical Chemistry (AACC). He is a Fellow of the National Academy of Clinical Biochemistry.
His awards include the Johnson and Johnson Award for Outstanding Research and Contributions to Clinical Biochemistry from the National Academy of Clinical Biochemistry; Morton K Schwartz Award for Outstanding Achievements in the field of Cancer Diagnostics from AACC; Carl Jolliff Award for Lifetime Achievements in Immunology and Immunodiagnostics from the Immunology Division of the AACC; Morton K Schwartz Award for significant contributions to the development of cancer diagnostics from the New York Metro Division of the AACC.; Abbott-ISOBM Award for Outstand research in oncology; National Award for Contributions in Education by the AACC; Outstanding Clinical Chemist Award by the Texas Section of the AACC; the Dean's Excellence Award from the University of Texas Graduate School of Biomedical Science; and the Distinguished Scientist Award from the CLAS.
Dr. Fritsche has lectured extensively for many years at international and national meetings of medical and professional societies and he is recognized internationally as an expert in the field of clinical chemistry, cancer diagnostics and laboratory medicine.
"Dr. Fritsche is a highly respected international authority in clinical chemistry and one of the world's leading experts on tumor biomarkers. We are extremely honored that he, with his vast and unique experience, has agreed to become our Chief Science Officer," stated Stephen D. Barnhill, MD. Executive Chairman of Aion Therapeutic. "Dr. Fritsche and I have been working together for more than 30 years on groundbreaking research utilizing artificial intelligence techniques primarily in the field of cancer diagnostics. We have co-authored numerous peer-reviewed publications and I look forward to working with Dr. Fritsche to continue our efforts to help patients globally."
"Dr. Barnhill is a scientific visionary having brought together the fields of medicine and mathematics in a way that has and will continue to benefit patients worldwide. Dr. Barnhill is the earliest proponent of the use of artificial intelligence in medicine and he is considered an international expert in this new field of medicine. It has been a great pleasure to work with him on cutting edge scientific discovery for more than 30 years," stated Dr. Herbert Fritsche. He added, "As a pioneer in artificial intelligence techniques in medicine and an inventor on more than 40 patents in this field, Dr. Barnhill's contribution to the science of machine learning in medical applications is remarkable and unprecedented. I look forward to continuing our efforts to develop state-of-the-art technology and unique treatment formulations to help patients worldwide."
Mr. Graham Simmonds, CEO of Aion Therapeutic, stated, "We welcome Dr. Fritsche to the growing team of international experts being established by Dr. Barnhill. We look forward to Dr. Fritsche's expertise guiding our scientific efforts to create unique treatment formulations and intellectual property including the use of genomics in the development of personalized medicine therapies."
About AI Pharma
Current AI techniques provides the backbone of our discovery methods, along with a unique and strategic geographic foundation in Jamaica, where the organization, in association with its Jamaican-based Cannabis License Authority (CLA) licensed medical cannabis partner, Apollon Formularies Jamaica, Ltd. has the requisite range of licenses and existing facilities to accommodate our discovery research.
- Jamaica is uniquely legal for medical cannabis via CLA approved licenses (which we have through our discovery partnership) and is one of the very few countries in the world where mushrooms (both edible and psychedelic) have never been made illegal and are openly sold. This allows AI Pharma to legally discover these unique combined formulations to build a large patent portfolio of blocking patents and products while most of the rest of the world is legally limited in this type of discovery.
- AI Pharma has a cultivation facility that is currently being prepared for mushrooms and will be operational in approximately sixty days.
- AI Pharma has an R&D facility, as well as, a processing laboratory to prepare mushroom extracts in their distilled research and treatment ready form.
- AI Pharma has leased space at Doc's Place International, an award winning (recently ranked #1 in the world by Edibles Magazine) health and wellness resort in Negril, Jamaica for medical cannabis patients that will now also be utilized for AI Pharma's patients as a treatment centre for psilocybin and combined psilocybin/cannabis based therapies.
About Aion Therapeutic Inc.
Aion Therapeutic Inc. (formerly, Osoyoos Cannabis Inc.) has a joint-venture agreement with a private, vertically-integrated licensed producer under the Cannabis Act (Canada) to offer contract tolling extraction services to third-party businesses. Additionally, the Company recently acquired 1196691 B.C. Ltd. d/b/a "PCAI Pharma" (www.pcai.ca) and its wholly-owned subsidiary AI Pharmaceuticals Jamaica Limited, a private corporation incorporated and operating under the laws of Jamaica. The business of AI Pharma involves, research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, the Company is creating a strong international intellectual property portfolio related to their discoveries
For further information, please contact:
Investor Relations & Financial Media
Integrity Media Inc.
team@integritymedia.com
Toll Free: (888) 216-3595
www.IntegrityMedia.com
Aion Therapeutic Inc.
Graham Simmonds
Executive Vice Chair & CEO
(416) 843-2881
DISCLAIMER & READER ADVISORY
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "may", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, PCAI and AI Pharma. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include regulatory and other third-party approvals, licensing and other risks. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/63558
copyright (c) newsfile corp. 2020